Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Mol Cancer Res. 2017 Jan 20;15(5):585–597. doi: 10.1158/1541-7786.MCR-16-0312

Figure 5. Stromal STAT1 influences progression of early stage breast cancer lesions in vivo.

Figure 5

A, Schematic depicting experimental strategy for intraductal injection experiments. Control CAFs were injected into one mammary fat pad (n = 5), while STAT1-depleted CAFs (shSTAT1) were injected into the contralateral fat pad (n = 5). After 24 hours, DCIS.COM cells were injected into the nipple of each mammary gland. B, Representative H&E images of tumor progress in glands injected with control CAFs (left) and shSTAT1 CAFs (right) at both 10× (top) and 40× (bottom). C, Mean percent of DCIS/IDC-like lesion per field of view in glands injected with control CAFs (n = 5) compared to glands injected with shSTAT1 CAFs (n = 5). D, Representative 40× images showing tumor lesions in glands injected with control CAFs (left) and shSTAT1 CAFs (right) stained with either human K8 (top row) or α-SMA (bottom row). DCIS: ductal carcinoma in situ, IDC: invasive ductal carcinoma, ADH: advanced ductal hyperplasia. E, Quantification of percent α-SMA+ cells per 40× field of view in 5 μm sections from mammary glands injected with sh.Control CAFs (left) or sh.STAT1 CAFs (right).